Job Opportunities Apollomics is currently reviewing candidates for the following positions: There are currently no positions posted. Please check back at another time. Subscribe Name First Last Email Subscribe to our newslettersNameThis field is for validation purposes and should be left unchanged. Press Releases November 16, 2023 Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer November 15, 2022 Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations September 14, 2022 Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp. July 26, 2022 Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer January 11, 2022 Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 January 4, 2022 Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
